Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer and inflammatory diseases. The company's lead asset, barzolvolimab, is a monoclonal antibody targeting KIT (CD117) in Phase 2b trials for chronic spontaneous urticaria and chronic inducible urticaria, with potential expansion into mast cell-driven diseases. With no commercial revenue, the stock trades on clinical trial readouts, regulatory milestones, and cash runway visibility.
Celldex operates a classic biotech R&D model: raise capital through equity offerings and strategic partnerships, invest in clinical trials to generate proof-of-concept data, then either commercialize internally or partner/license assets to larger pharma companies. The company's value derives from the probability-adjusted net present value of its pipeline assets, primarily barzolvolimab. With a current ratio of 13.01 and minimal debt, the company maintains substantial cash reserves (estimated $300-400M) to fund operations through multiple clinical catalysts. Monetization occurs through regulatory approval and product launch, partnership economics (upfront payments, milestones, royalties), or acquisition by a larger pharmaceutical company.
Barzolvolimab Phase 2b data readouts in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) - primary endpoints on itch severity and urticaria activity scores
FDA regulatory pathway clarity and potential breakthrough therapy designation for barzolvolimab in urticaria indications
Clinical trial initiation announcements for barzolvolimab expansion into additional mast cell-driven diseases (hereditary alpha tryptasemia, systemic mastocytosis)
Cash runway updates and equity financing announcements - dilution concerns vs. funding adequacy
Strategic partnership or licensing deals that validate platform technology and provide non-dilutive capital
Clinical trial failure risk - barzolvolimab Phase 2b trials may not meet primary endpoints, rendering the asset non-viable and eliminating majority of company value
Regulatory approval uncertainty - even with positive Phase 2 data, FDA may require additional trials or reject approval, extending timelines and capital requirements by years
Competitive landscape evolution - multiple companies developing anti-KIT therapies and alternative urticaria treatments could erode market opportunity or create pricing pressure
Novartis' Xolair (omalizumab) dominates chronic urticaria market with established efficacy and reimbursement, creating high bar for differentiation
Pipeline competition from other anti-KIT antibodies and BTK inhibitors in development for mast cell diseases may reach market first or demonstrate superior profiles
Large pharma companies with greater resources could accelerate competing programs or acquire rival assets
Equity dilution risk - company will require additional capital raises before potential commercialization, diluting existing shareholders (likely 20-40% dilution over next 2-3 years)
Cash burn acceleration - clinical trial expansions or manufacturing scale-up could increase quarterly burn rate beyond current $15-20M, shortening runway
Valuation compression risk - with no revenue and negative cash flow, stock vulnerable to biotech sector sentiment shifts and risk-off environments
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as R&D spending is pre-committed and not tied to consumer demand. However, severe recessions can impact ability to raise capital and affect acquisition appetite from larger pharma companies.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (barzolvolimab revenues unlikely before 2028-2029). Higher rates also increase opportunity cost of holding non-income-producing growth stocks vs. fixed income. Conversely, the company's substantial cash balance benefits from higher yields on short-term investments, partially offsetting burn rate. Rate environment also affects M&A activity as acquirers face higher financing costs.
Minimal - Company has zero debt and strong current ratio of 13.01. Not dependent on credit markets for operations, though equity capital markets access is critical for funding. Broader credit stress can reduce institutional investor risk appetite for pre-revenue biotechs.
growth - High-risk, high-reward profile attracts biotech specialists, venture-style investors, and momentum traders betting on binary clinical catalysts. Not suitable for value or income investors given negative cash flow and no dividends. Institutional holders typically specialized healthcare funds with expertise evaluating clinical data and regulatory pathways.
high - Clinical-stage biotechs exhibit extreme volatility around data readouts (30-50% single-day moves common). Stock highly sensitive to sector rotation, with beta likely 1.5-2.0x vs. broader market. Limited liquidity at $1.5B market cap amplifies price swings. Recent 3-month decline of 9.8% reflects typical pre-catalyst consolidation.
